特立帕肽联合仙灵骨葆治疗骨质疏松的效果及对患者骨密度水平的影响

The Effect of Teriparatide Combined Xianlinggubao Treatment of Osteoporosis and Effects on Bone Mineral Density

目的:探讨特立帕肽联合仙灵骨葆治疗骨质疏松的效果及对患者骨密度水平的影响。方法:选取骨质疏松症患者88例,按照随机数字表法,分为对照组(n=44)和观察组(n=44)。对照组采用特里帕肽进行治疗,观察组在对照组基础上,加用仙灵骨葆胶囊进行治疗,比较两组治疗前、治疗12周后及治疗24周后的骨密度水平、骨标志物变化情况、症状积分改善情况。结果:经过相应药物治疗后,观察组腰椎骨密度高于对照组,差异有统计学意义(P<0.05);观察组治疗后的血清骨钙素(sOC)和骨碱性磷酸酶(sBAP)高于对照组,差异有统计学意义(P<0.05);两组不良反应发生情况差异无统计学意义(P>0.05)。结论:特立帕肽联合仙灵骨葆治疗骨质疏松的效果显著,可有效提高患者的骨密度水平,安全性高,值得在临床上进一步推广应用。

Objective：To investigate the effects of Teriparatide combined Xianlinggubao treatment of osteoporosis and its effect on bone mineral density.Method：88 patients with osteoporosis were selected and divided into the control group（n=44） and the observation group（n=44） according to random number table method.The control group using the Teriparatide treatment,the observation group used Xianlinggubao capsule for treatment based on the control group,before and after treatment for 12 weeks and 24 weeks after treatment of bone density,bone markers,improvement of symptoms between the two groups were compared.Result：After treatment,the observation group of lumbar bone mineral density was higher than the control group,the difference was statistically significant（P〈0.05）, after treatment,the serum osteocalcin（sOC） and bone alkaline phosphatase（sBAP） in the observation group were higher than the control group,the differences were statistically significant（P〈0.05）,the incidence of adverse reactions of the two groups had no significant difference（P〉0.05）.Conclusion：Teriparatide combined Xianlinggubao treatment of osteoporosis has significant effect,can effectively improve the bone mineral density,high safety,worthy of further clinical application.